Based on histopathology, there are three main groups of PDXs: adenocarcinomas (55%), neuroendocrine tumors (31%), and those with mixed pathology that are positive for both the AR and neuroendocrine markers to varying degrees (14%; Fig. 1). This evidence concerns the gene AR and adenocarcinoma.